Valeant to sell assets for $2.12 billion to ease debt load
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Valeant (VRX) Asset Sales 'Somewhat Encouraging' But 2017 Seen as Transition Year - BTIG
January 10, 2017 12:11 PM ESTBTIG analyst Timothy Chiang weighed in on Valeant Pharmaceuticals (NYSE: VRX) sold its Dendreon business for ~$820M (Valeant paid ~$415M for this back in 2015) and three skin care product lines (CeraVe, AcneFree, and AMBI) for ~$1.3B (~7.7x annualized sales of $168M). Proceeds... More
Valeant Pharma (VRX) to Sell Skincare Brands To L'Oreal For $1.3B
January 10, 2017 5:48 AM ESTValeant Pharmaceuticals International, Inc. (NYSE: VRX) entered into an agreement to sell its CeraVe, AcneFree and AMBI skincare brands to L'Oréal for $1.3 billion in cash. The CeraVe, AcneFree, and AMBI product lines have annualized revenue of approximately of $168 million.
"We are pleased to announce the progress we are making in reshaping our product portfolio and driving value for our shareholders," said Valeant CEO Joseph... More
